Gaëtane Nocturne

Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study

Xavier Mariette, Raphaèle Séror, Luca Quartuccio et al. · Annals of the Rheumatic Diseases · 2013 · 308 citations

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 290 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +9

Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome

Gaëtane Nocturne, Alexandre Virone, Wan‐Fai Ng et al. · Arthritis & Rheumatology · 2015 · 191 citations

Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort

Jacques‐Eric Gottenberg, Raphaèle Séror, Corinne Miceli‐Richard et al. · PLoS ONE · 2013 · 177 citations · Full text

Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation

Michaël Mingueneau, Saida Boudaoud, Scott Haskett et al. · Journal of Allergy and Clinical Immunology · 2016 · 168 citations

Inflammation, Rheumatology, Autoimmune Disease +14